MX2016016458A - Métodos para repetir tratamiento de síndrome del intestino irritable (ibs). - Google Patents

Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).

Info

Publication number
MX2016016458A
MX2016016458A MX2016016458A MX2016016458A MX2016016458A MX 2016016458 A MX2016016458 A MX 2016016458A MX 2016016458 A MX2016016458 A MX 2016016458A MX 2016016458 A MX2016016458 A MX 2016016458A MX 2016016458 A MX2016016458 A MX 2016016458A
Authority
MX
Mexico
Prior art keywords
ibs
repeat
methods
syndrome treatment
lbs
Prior art date
Application number
MX2016016458A
Other languages
English (en)
Other versions
MX381919B (es
Inventor
Bortey Enoch
Forbes William
Golden Pam
Paterson Craig
Original Assignee
Salix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Inc
Publication of MX2016016458A publication Critical patent/MX2016016458A/es
Publication of MX381919B publication Critical patent/MX381919B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Image Input (AREA)

Abstract

La presente invención proporciona nuevos métodos y kits para la repetición de tratamiento contra lBS. Un método selecciona a un sujeto que tiene Síndrome de Intestino Irritable (lBS) para la repetición del tratamiento con rifaximina, en donde el método incluye la identificación de un sujeto que se ha tratado previamente con rifaximina, que es un respondedor, y en donde el sujeto actualmente necesita el tratamiento con lBS.
MX2016016458A 2014-06-30 2015-05-04 Métodos para repetir tratamiento de síndrome del intestino irritable (ibs). MX381919B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462019388P 2014-06-30 2014-06-30
US201462036097P 2014-08-11 2014-08-11
PCT/US2015/029083 WO2016003536A1 (en) 2014-06-30 2015-05-04 Methods for retreating irritable bowel syndrome (ibs)

Publications (2)

Publication Number Publication Date
MX2016016458A true MX2016016458A (es) 2017-07-13
MX381919B MX381919B (es) 2025-03-13

Family

ID=55019821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016458A MX381919B (es) 2014-06-30 2015-05-04 Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).

Country Status (8)

Country Link
US (3) US20170105977A1 (es)
EP (1) EP3160467B1 (es)
JP (1) JP6671360B2 (es)
KR (1) KR102318025B1 (es)
CN (1) CN106999477B (es)
AU (1) AU2015284782B2 (es)
MX (1) MX381919B (es)
WO (1) WO2016003536A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
EP3569690B1 (en) 2011-12-01 2024-08-28 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
CN108117991B (zh) * 2017-11-03 2021-03-30 湖南海路生物科技有限公司 检测乙酸、异丁酸和/或戊酸含量的产品在制备揭示便秘患者的肠道微生态存在失衡的产品中的用途
CN111328279B (zh) * 2017-11-10 2023-04-14 科斯莫科技有限公司 口服利福霉素sv组合物
WO2020033130A1 (en) * 2018-08-06 2020-02-13 The Johns Hopkins University Treatment of irritable bowel syndrome with molybdenum
CA3124970A1 (en) * 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
CN113645968A (zh) * 2019-03-18 2021-11-12 西达赛奈医疗中心 治疗胃肠疾病和障碍的组合物和方法
AU2021241001A1 (en) * 2020-03-24 2022-10-20 Bausch Health Ireland Limited Solid dispersions of rifaximin for the treatment of Overt Hepatic Encephalopathy
WO2023039276A1 (en) * 2021-09-13 2023-03-16 Curtails Llc Use of ibat inhibitors and antimicrobials for the treatment of diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
ES2114502B1 (es) * 1996-07-29 1999-07-01 Univ Santiago Compostela Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas.
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
CA2643364C (en) * 2006-03-09 2017-06-06 Salix Pharmaceuticals, Inc. Rifaximin anti-rectal dysfunction preparation
ES2538478T3 (es) * 2006-08-02 2015-06-22 Salix Pharmaceuticals, Inc. Métodos para el tratamiento de enteritis por radiación
KR101480732B1 (ko) * 2006-09-22 2015-01-21 씨아이피엘에이 엘티디. 리팍시민
WO2008122965A2 (en) * 2007-04-04 2008-10-16 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
EP2011496A1 (en) * 2007-07-03 2009-01-07 Indena S.P.A. Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions
WO2009047801A1 (en) * 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
SG10201607926VA (en) * 2008-02-25 2016-11-29 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
ES2727728T3 (es) * 2008-02-26 2019-10-18 Salix Pharmaceuticals Ltd Métodos para el tratamiento del síndrome del intestino irritable
AU2009244190B2 (en) * 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
EP2350096B1 (en) * 2008-10-02 2019-12-11 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
JP2012522019A (ja) * 2009-03-27 2012-09-20 サリックス ファーマスーティカルズ，リミテッド 腸管前処置のための組成物およびその使用方法
EP2437603A4 (en) * 2009-06-02 2012-12-12 Salix Pharmaceuticals Ltd METHODS OF TREATING HEPATIC ENCEPHALOPATHY
CA2773982C (en) * 2009-09-13 2018-12-04 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
ES2986825T3 (es) * 2011-11-02 2024-11-12 Salix Pharmaceuticals Inc Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
EA201590522A1 (ru) * 2012-09-13 2015-06-30 Саликс Фармасьютикалс, Инк. Способы введения рифаксимина для снижения веса и лечения ожирения

Also Published As

Publication number Publication date
JP2017520624A (ja) 2017-07-27
WO2016003536A1 (en) 2016-01-07
US20200230116A1 (en) 2020-07-23
JP6671360B2 (ja) 2020-03-25
EP3160467A1 (en) 2017-05-03
AU2015284782B2 (en) 2020-05-07
CN106999477A (zh) 2017-08-01
KR102318025B1 (ko) 2021-10-27
MX381919B (es) 2025-03-13
EP3160467B1 (en) 2021-03-10
KR20170038810A (ko) 2017-04-07
CN106999477B (zh) 2020-04-10
EP3160467A4 (en) 2018-02-07
US20200276170A1 (en) 2020-09-03
US20170105977A1 (en) 2017-04-20
AU2015284782A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
MX2016016458A (es) Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
AR134579A2 (es) Proceso para la preparación de un compuesto de diariltiohidantoína
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MY193661A (en) Anti-tim3 antibodies and methods of use
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
MX2021010460A (es) Metodo de tratamiento con tradipitant.
SG11201702728UA (en) Illumination system, inspection tool with illumination system, and method of operating an illumination system
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MX2018000337A (es) Microorganismos para la produccion de putrescina u ornitina y procedimiento para la produccion de putrescina u ornitina usando los mismos.
MX2017004516A (es) Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
TW201613587A (en) Medical treatments based on anamorelin
GB2562955B (en) Attachment device, retainer & associated method of use
EP3479227A4 (en) CORRELATION OF MULTIPLE SOURCES
MX369857B (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
EP3490547A4 (en) TREATMENT METHOD
JP2014207895A5 (ja) アシネトバクター属菌の遺伝子型タイピング法及びこれに用いるプライマーセット
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
BR112017012087A2 (pt) métodos de identificação de genes codificantes e não codificantes coexpressados, e sistema
MX2019002673A (es) Composiciones y metodos para tratar demencia.
EA201691203A1 (ru) Твёрдые формы тенофовира
CL2016003417A1 (es) Method for detecting h2o2 resistance in crustaceans
GB201615330D0 (en) Method of diagnosis
GEAP201814327A (en) Treatment regimen tiacumicin compound